QuickView: Solving ophthalmic gene therapy
Avalanche is well capitalised to deliver all important proof-of-concept data in 2015 with trial readout in wet AMD. By combining its gene therapy technology platform with vascular endothelial growth factor (VEGF) trap molecules, Avalanche is aiming to break into the $6bn exudative AMD market. With $290m in cash and a Regeneron licensing deal for orphan diseases, Avalanche is well placed to deliver on its clinical programmes.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.